



Date: June 10, 2022

Subject: BNTX1 Options - Expiration Pricing Consideration

BNTX1 (adjusted BioNTech SE options) will be subject to special pricing consideration in expiration processing on June 10, 2022. The pricing consideration is due to the undetermined net cash amount included in the option deliverable of BNTX1 as indicated below. These options will continue to be subject to normal exercise based on customary exercise thresholds in OCC's Ex-by-Ex processing.

MEMBERS SHOULD ADVISE THEIR CUSTOMERS TO TAKE THE FOLLOWING CONSIDERATIONS INTO ACCOUNT IN DECIDING TO EXERCISE, OR NOT TO EXERCISE, THESE OPTIONS.

BNTX1

BNTX1 options are adjusted BioNTech SE options, adjusted June 2, 2022 (see OCC Information Memo #50522). The deliverable of BNTX1 options is:

NEW DELIVERABLE

PER CONTRACT:

- 1) 100 BioNTech SE (BNTX) American Depositary Shares
- 2) Approximately \$153.42 Cash (\$1.534223 x 100)

As of June 10, 2022, the BNTX Distribution Agent has not determined the final net dividend amount.

For purposes of calculating an BNTX1 price for use in expiration processing, OCC will use the following formula:

$$\text{BNTX1} = \text{BNTX} + 1.5342$$

For example, if BNTX closes at 149.27, the BNTX1 price would be:

$$\text{BNTX1} = 149.27 + 1.5342 = 150.80$$

This formula includes an estimate for the value of the cash in the deliverable and not the actual final net cash dividend amount applicable in the distribution.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.